Estrella Immunopharma Inc
For the period ended Dec 31, 2023. Filed Feb 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 14, 2024
ESLA$0.75+45.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Balance Sheets
| As of December 31, 2023 | As of June 30, 2023 | |
|---|---|---|
| (Unaudited) | ||
| Current Assets | ||
| Current assets: | ||
| Cash | $9,046,015 | $2,479,146 |
| Prepaid expenses | 401,248 | - |
| Extension note receivable | - | 273,066 |
| Total current assets | 9,447,263 | 2,752,212 |
| Other Assets | ||
| Deferred transaction costs | - | 276,187 |
| Total Assets | $9,447,263 | $3,028,399 |
| Liabilities, Preferred Stock and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable - related party | $77,076 | $9,333,146 |
| Other payables and accrued liabilities | 270,579 | 398,781 |
| Accrued liability - related party | 6,000 | 22,000 |
| Franchise tax payables | 4,359 | 4,297 |
| Income tax payables | 40,719 | - |
| Total current liabilities | 398,733 | 9,758,224 |
| Non-current liabilities: | ||
| Other liability | - | 12,725 |
| Total non-current liabilities | - | 12,725 |
| Total Liabilities | 398,733 | 9,770,949 |
| Commitments and Contingencies (Note 8) | ||
| Preferred Stock* | ||
| Series A Preferred Stock, $0.0001 par value, 15,000,000 shares authorized; 0 and 1,203,695 shares issued and outstanding as of December 31, 2023 and June 30, 2023, respectively | - | 5,000,000 |
| Series AA Preferred Stock, $0.0001 par value, 105,000,000 shares authorized; 0 and 25,277,591 shares issued and outstanding as of December 31, 2023 and June 30, 2023, respectively | - | - |
| Stockholders’ Equity (Deficit): | ||
| Common stock, $0.0001 par value; 250,000,000 shares authorized; 35,201,232 and 978,243 shares issued and outstanding as of December 31, 2023 and June 30, 2023, respectively* | 3,520 | 98 |
| Additional paid-in capital | 24,124,684 | 445,905 |
| Accumulated deficit | (15,079,674) | (12,188,553) |
| Total Stockholders’ Equity (Deficit) | 9,048,530 | (11,742,550) |
| Total Liabilities, Preferred Stock and Stockholders’ Equity (Deficit) | $9,447,263 | $3,028,399 |
| * | Giving retroactive effect to reverse recapitalization effected on September 29, 2023 to reflect exchange ratio of approximately 0.2407 as described in Note 3 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.